{'fraction_non_alphanumeric': 0.011347517730496455, 'fraction_numerical': 0.00851063829787234, 'mean_word_length': 5.788461538461538, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tropical Medicine & International Health

A review of the sources of heterogeneity in outcomes and shortcomings in the designs of clinical trials of cutaneous leishmaniasis treatments documents changes in reporting before and after the publication of the CONSORT statement. Lack of standardisation, compounded by the small number of trials relative to the magnitude of the disease in its multiple forms, and the range of treatments tested explains why evidence to inform treatment guidelines is generally weak for cutaneous leishmaniasis. Adopting standardised methods will improve the quality and consistency of clinical trials, and ultimately yield better treatments for cutaneous leishmaniasis. 448–475